Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cu-64 TP3805 PET/CT in Urothelial Cancer
NCT03039413Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2016
- Primary completion
- May 2019
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NV-VPAC1 in urothelial carcinoma (UC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Feasibility of Cu-64-TP3805 to detect UC as determined by post-surgical histology. Started Sep 2016; status: completed.
02
Drugs
NV-VPAC1
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03039413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03039413.